Combined low-dose-rate brachytherapy and external beam radiation for cervical cancer: experience over ten years.

I Han, C Orton, F Shamsa, K Hart, A Strowbridge, G Deppe, A Porter, P J Chuba
{"title":"Combined low-dose-rate brachytherapy and external beam radiation for cervical cancer: experience over ten years.","authors":"I Han, C Orton, F Shamsa, K Hart, A Strowbridge, G Deppe, A Porter, P J Chuba","doi":"10.1002/(SICI)1520-6823(1999)7:5<289::AID-ROI4>3.0.CO;2-X","DOIUrl":null,"url":null,"abstract":"<p><p>Cervical cancer was treated with a combination of external beam and intracavitary radiation during a 10-year period at Wayne State University. Data were collected for 216 patients treated radically with external beam radiation (EBRT) and low-dose-rate brachytherapy for cervical cancer between 1980 and 1991 at Wayne State University. Patient distribution by stage was IB, 20.8%; IIA, 7.4%; IIB, 26.9%; IIIA, 1.8%; IIIB, 40.7%; and IVA, 2.3 %. Survival curves were constructed using Kaplan-Meier methods and differences between groups were tested for significance using the log-rank test. Multivariate analysis was done using the Cox proportional hazards model. With a median follow-up of 114 months, actuarial disease-free survival for all patients was 60% at 5 years and 55% at 10 years. Actuarial 5-year survival for Stage IB was 79%; for Stage II, 59%; and for Stage III, 53%. There were 14/216 (6%) of patients with severe late complications. On univariate analysis, race was found to be statistically significant, with Caucasian patients having better survival than African American (P = 0.03). The survival for patients treated in shorter overall times was significantly higher (P<0.001), especially with treatment completion in under 58 days. The stepwise Cox multivariate analysis provided the following significant results: race (African American vs. Caucasian; P = 0.04, RR = 1.6), Stage (II vs. I, P = 0.004, RR = 2.6), Stage (III vs. I; P = 0.004, RR = 2.5), and overall treatment time (P = 0.006, RR = 1.62). Rates of local control, survival, and complications among women treated with combined external beam and intracavitary radiation for cervix cancer were similar to those of prior retrospective studies.</p>","PeriodicalId":20894,"journal":{"name":"Radiation oncology investigations","volume":"7 5","pages":"289-96"},"PeriodicalIF":0.0000,"publicationDate":"1999-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Radiation oncology investigations","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1002/(SICI)1520-6823(1999)7:5<289::AID-ROI4>3.0.CO;2-X","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Cervical cancer was treated with a combination of external beam and intracavitary radiation during a 10-year period at Wayne State University. Data were collected for 216 patients treated radically with external beam radiation (EBRT) and low-dose-rate brachytherapy for cervical cancer between 1980 and 1991 at Wayne State University. Patient distribution by stage was IB, 20.8%; IIA, 7.4%; IIB, 26.9%; IIIA, 1.8%; IIIB, 40.7%; and IVA, 2.3 %. Survival curves were constructed using Kaplan-Meier methods and differences between groups were tested for significance using the log-rank test. Multivariate analysis was done using the Cox proportional hazards model. With a median follow-up of 114 months, actuarial disease-free survival for all patients was 60% at 5 years and 55% at 10 years. Actuarial 5-year survival for Stage IB was 79%; for Stage II, 59%; and for Stage III, 53%. There were 14/216 (6%) of patients with severe late complications. On univariate analysis, race was found to be statistically significant, with Caucasian patients having better survival than African American (P = 0.03). The survival for patients treated in shorter overall times was significantly higher (P<0.001), especially with treatment completion in under 58 days. The stepwise Cox multivariate analysis provided the following significant results: race (African American vs. Caucasian; P = 0.04, RR = 1.6), Stage (II vs. I, P = 0.004, RR = 2.6), Stage (III vs. I; P = 0.004, RR = 2.5), and overall treatment time (P = 0.006, RR = 1.62). Rates of local control, survival, and complications among women treated with combined external beam and intracavitary radiation for cervix cancer were similar to those of prior retrospective studies.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
宫颈癌的低剂量近距离放射治疗和外照射联合疗法:十年来的经验。
在韦恩州立大学的 10 年间,宫颈癌患者接受了外照射和腔内放射的综合治疗。我们收集了韦恩州立大学在1980年至1991年期间采用体外射束辐射(EBRT)和低剂量近距离放射治疗宫颈癌的216名患者的数据。患者的分期分布为:IB,20.8%;IIA,7.4%;IIB,26.9%;IIIA,1.8%;IIIB,40.7%;IVA,2.3%。采用 Kaplan-Meier 方法绘制了生存曲线,并用对数秩检验法检验了组间差异的显著性。采用考克斯比例危险模型进行多变量分析。中位随访时间为114个月,所有患者5年的精算无病生存率为60%,10年的精算无病生存率为55%。IB 期患者的 5 年精算生存率为 79%,II 期为 59%,III 期为 53%。216例患者中有14例(6%)出现严重的晚期并发症。单变量分析发现,种族具有统计学意义,白种人的生存率高于非裔美国人(P = 0.03)。总治疗时间较短的患者的生存率明显更高(P = 0.05)。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Molecular and anatomic considerations in the pathogenesis of breast cancer. Telomeric length in individuals and cell lines with altered p53 status. Effect of combined adoptive immunotherapy and radiotherapy on tumor growth. PSA kinetics following I-125 radioactive seed implantation in the treatment of T1-T2 prostate cancer. Hyperfractionated and accelerated-hyperfractionated radiotherapy for glioblastoma multiforme.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1